Table 4.
The association between different SGLT2 inhibitors and FG occurrence.
| Drug | N | ROR | PRR | IC | EBGM |
|---|---|---|---|---|---|
| (95% two-sided CI) | (χ2) | (IC025) | (EBGM05) | ||
| Canagliflozin | 190 | 18.76 (16.22, 21.70) | 18.60 (3058.02) | 4.17 (3.61) | 18.00 (15.94) |
| Canagliflozin/metformin | 9 | 20.12 (10.43, 38.81) | 19.93 (161.61) | 4.31 (2.24) | 19.90 (11.48) |
| Dapagliflozin | 96 | 22.89 (18.68, 28.04) | 22.64 (1952.68) | 4.48 (3.65) | 22.27 (18.79) |
| Dapagliflozin/saxagliptin | 0 | — | — | — | — |
| Dapagliflozin/metformin | 12 | 34.86 (19.69, 61.73) | 34.28 (387.09) | 5.10 (2.88) | 34.21 (21.21) |
| Empagliflozin | 209 | 46.70 (40.61, 53.70) | 45.70 (8798.23) | 5.46 (4.75) | 44.02 (39.16) |
| Empagliflozin/linagliptin | 10 | 23.82 (12.76, 44.46) | 23.55 (215.66) | 4.56 (2.44) | 23.51 (13.95) |
| Empagliflozin/metformin | 13 | 54.79 (31.56, 95.12) | 53.36 (666.70) | 5.73 (3.30) | 53.24 (33.56) |
| Ertugliflozin | 3 | 18.68 (5.99, 58.24) | 18.51 (49.70) | 4.21 (1.35) | 18.50 (7.15) |
| Ertugliflozin/metformin | 0 | — | — | — | — |
| Ertugliflozin/sitagliptin | 0 | — | — | — | — |
| Ipragliflozin | 0 | — | — | — | — |
| Luseogliflozin | 0 | — | — | — | — |
| Tofogliflozin | 0 | — | — | — | — |